Published in Expert Rev Mol Diagn on July 01, 2012
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol (2013) 1.17
The mathematical limits of genetic prediction for complex chronic disease. J Epidemiol Community Health (2015) 0.94
Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine (2013) 0.90
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One (2014) 0.87
Pharmacogenomics in oncology care. Front Genet (2014) 0.82
Integrating genetic and genomic information into effective cancer care in diverse populations. Ann Oncol (2013) 0.78
Identifying predictive markers for personalized treatment selection. Biometrics (2016) 0.78
Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol (2017) 0.75
Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature. BMJ Open (2016) 0.75
Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. J Pers Med (2013) 0.75
Personalized medicine and the clinical laboratory. Einstein (Sao Paulo) (2014) 0.75
A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol (2015) 0.75
Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine. Hum Pathol (2014) 0.75
Widening participation would be key in enhancing bioinformatics and genomics research in Africa. Appl Transl Genom (2015) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56
Targeted cancer therapy. Nature (2004) 7.81
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res (2008) 6.03
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA (2006) 5.51
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol (2008) 4.90
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res (2010) 4.51
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol (2011) 4.32
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (2011) 3.60
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 3.59
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol (2009) 3.15
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev (2008) 3.13
Patient time costs associated with cancer care. J Natl Cancer Inst (2007) 2.90
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol (2009) 2.26
Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res (2007) 2.15
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res (2003) 2.04
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov (2012) 1.96
Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet (2008) 1.96
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov (2010) 1.91
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control (2009) 1.77
Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol (2005) 1.75
Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res (2007) 1.71
High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol (2011) 1.70
The cell cycle and cancer. J Pathol (2011) 1.67
Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med (2009) 1.56
Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol (2007) 1.54
Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med (2010) 1.47
Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc (2006) 1.43
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood (2011) 1.42
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res (2004) 1.40
Integrating biomarkers in clinical trials. Expert Rev Mol Diagn (2011) 1.24
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood (2011) 1.16
Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov (2011) 1.14
Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res (2012) 1.09
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn (2011) 1.08
The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program (2006) 1.03
Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J (2007) 1.02
KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. Adv Anat Pathol (2010) 1.01
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J Clin Oncol (2011) 0.98
BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. PLoS One (2012) 0.97
Current treatment strategies in chronic myeloid leukemia. Curr Opin Hematol (2012) 0.92
Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn (2011) 0.90
Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology. Breast J (2007) 0.89
Trends in abnormal cancer screening results in the United States of America. J Med Screen (2007) 0.88
Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? J Proteomics (2011) 0.88
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Am J Hematol (2009) 0.84
The story of chronic myeloid leukaemia. Br J Haematol (2000) 0.84
PKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients. Int J Breast Cancer (2012) 0.83
Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Acta Haematol (2004) 0.83
Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. Am J Clin Pathol (2000) 0.83
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer. Breast Cancer Res (2011) 0.82
An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. Adv Ther (2011) 0.81
History of acute promyelocytic leukemia: a tale of endless revolution. Mediterr J Hematol Infect Dis (2011) 0.81
Microgranular variant of acute promyelocytic leukemia with normal conventional cytogenetics, negative PML/RARA FISH and positive PML/RARA transcripts by RT-PCR. Cancer Genet (2011) 0.80
Market watch: emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov (2010) 0.80
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med (2013) 22.73
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 19.08
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med (2008) 9.13
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet (2009) 8.42
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science (2012) 5.34
Genomewide association studies of stroke. N Engl J Med (2009) 5.29
Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet (2009) 5.20
DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med (2011) 4.98
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet (2004) 4.95
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet (2009) 4.56
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology (2004) 4.42
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet Med (2012) 4.04
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med (2004) 3.32
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med (2012) 3.18
NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet (2009) 3.18
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
The landscape of recombination in African Americans. Nature (2011) 3.06
Long-range LD can confound genome scans in admixed populations. Am J Hum Genet (2008) 3.06
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02
Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation (2010) 2.95
Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol (2006) 2.94
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation (2010) 2.78
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology (2002) 2.66
Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. PLoS One (2013) 2.65
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet (2010) 2.51
Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. Proc Natl Acad Sci U S A (2010) 2.47
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology (2010) 2.45
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol (2011) 2.37
The absence of intrarenal ACE protects against hypertension. J Clin Invest (2013) 2.31
Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn (2008) 2.24
Prospective study of particulate air pollution exposures, subclinical atherosclerosis, and clinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). Am J Epidemiol (2012) 2.23
A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet (2003) 2.17
Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol (2006) 2.14
Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. Diabetes Care (2010) 2.14
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet (2012) 2.12
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes (2011) 2.09
Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol (2008) 2.09
Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians. Am J Hypertens (2007) 2.06
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation (2011) 1.96
Standards and guidelines for CFTR mutation testing. Genet Med (2002) 1.94
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet (2011) 1.92
Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet (2008) 1.89
Mouse model for human arginase deficiency. Mol Cell Biol (2002) 1.88
College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med (2014) 1.84
Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet (2010) 1.83
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Hum Mol Genet (2010) 1.81
Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes (2003) 1.81
Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care (2010) 1.80
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death. J Am Coll Cardiol (2011) 1.80
Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes (2007) 1.79
Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the Insulin Resistance Atherosclerosis Family Study. Diabetes (2008) 1.78
Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Hum Mol Genet (2011) 1.77
Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Hum Mol Genet (2012) 1.77
Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab (2007) 1.76